Androgen deprivation therapy is associated with decreased second primary lung cancer risk in the United States veterans with prostate cancer

• Type of Material: Article
• Authors: Kyungsuk Jung, Fox Chase Cancer Center; Jong Chul Park, Harvard Medical School; Hyunseok Kang, Johns Hopkins University; Johann Brandes, Emory University
• Language: English
• Date: 2018-08-11
• Publisher: Korean Society of Epidemiology
• Publication Version: Final Published Version
• Copyright Statement: ©2018, Korean Society of Epidemiology
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.4178/epih.e2018040
• Title of Journal or Parent Work: Epidemiology and Health
• Volume: 40
• Start Page: e2018040
• End Page: e2018040
• Grant/Funding Information: This work was supported by Veteran’s Health Administration 1IK2BX001283-01 and NCI 5P50CA128613-02 to JCB.
• Keywords: Science & Technology; Life Sciences & Biomedicine; Lung neoplasms; ESTROGEN; Veterans; Prostatic neoplasms; Androgen antagonists; TESTOSTERONE; Public, Environmental & Occupational Health; WHITE MEN; ANTIBODY; Hormones; AGE; SAFETY; RECEPTOR
• Research Categories: Health Sciences, Oncology

Abstract

OBJECTIVES: We investigated whether androgen deprivation therapy (ADT) in prostate cancer patients was associated with a decreased risk for second primary lung cancer in US veterans. METHODS: Prostate cancer diagnoses in the US Veterans Affairs Cancer Registry between 1999 and 2008 were identified. Use of hormonal therapy and diagnoses of second primary lung cancer were determined from the registry. Synchronous prostate and lung cancers, defined as 2 diagnoses made within 1 year, were excluded from the analysis. Cancer-free survival was estimated using the Kaplan-Meier method and hazard ratios were estimated using Cox proportional hazard models. RESULTS: Among the 63,141 identified patients with prostate cancer, 18,707 subjects were eligible for the study. Hormonal therapy was used in 38% of patients and the median follow-up period was 28 months. ADT use was associated with longer lung cancer-free survival in prostate cancer patients (log-rank p=0.01). After adjusting for age, race, smoking and prostate cancer stage, ADT use was associated with decreased lung cancer risk by 15, 21, and 24% after 1, 2, and 3 years, respectively. CONCLUSIONS: ADT in prostate cancer patients may be associated with decreased second primary lung cancer risk among US veterans.